Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.

Julius L Katzmann Christian BeckerAikaterini BilitouUlrich Laufs

Published in: PloS one (2022)

A considerably larger proportion of cardiovascular high- and very-high-risk patients can achieve guideline-recommended LDL-C goals with escalated lipid-lowering medication. Bempedoic acid is projected to substantially decrease the need for PCSK9 inhibitor treatment to achieve LDL-C targets, associated with reduced drug costs albeit with fewer prevented events.

Keyphrases

low density lipoprotein
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
climate change
emergency department
combination therapy
peritoneal dialysis
patient reported outcomes